Compare Nerdwallet Inc (NRDS) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nerdwallet Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Nerdwallet Inc trades at $9.78 (market cap $627.09M), while Vertex Pharmaceuticals Incorporated trades at $528.01 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 211.8× Nerdwallet Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Nerdwallet Inc nearer its low. Which is the better fit depends on your goals.
| NRDS | VRTX | |
|---|---|---|
Market Cap | $627.09M | $132.79B |
Sector | Financials | Health |
52-Week High | $15.93 | $529.65 |
52-Week Low | $7.58 | $376.62 |
Enterprise Value | $541.39M | $126.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NerdWallet (NRDS) trades at $9.91, up 12.1% in the past 24 hours, with a bullish technical signal from moving averages. The company shows strong revenue growth from $539M in 2022 to $837M in 2025, with net income turning positive to $48.7M. Recent Q2 2026 earnings missed expectations at $0.07 per share versus $0.0934 expected, though Q1 and Q4 2025 beat estimates. Valuation metrics appear attractive with a P/E of 10.9 and P/S of 0.82.
The outlook remains positive with analyst consensus favoring Buy ratings (66.7%) and projected 27.9% upside potential. Key risks include execution challenges in shifting from SEO-dependent referrals and competitive pressure in financial guidance markets. Strong cash flow generation and improving profitability support the bullish case, though investors should monitor quarterly earnings consistency.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nerdwallet Inc
Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.
Read more on NRDS →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
